SALEM INVESTMENT COUNSELORS INC
Position in AKTS — Aktis Oncology, Inc.
CIK 884423
WINSTON-SALEM, NC
Position in AKTS
as of Jun 30, 2026
· filed Jul 14, 2026
Position Value
$32,230
+$14,340 QoQ
Shares Held
1,000
0.0% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#3
of 8 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in AKTS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026SALEM INVESTMENT COUNSELORS INC holds $2,462,425 across 22 Biotechnology names. AKTS ranks #7 (1.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CAI |
Caris Life Sciences, Inc.
|
100,000 | $1,782,000 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
494 | $245,384 | |
| 3 | FTRE |
Fortrea Holdings Inc.
|
5,746 | $99,980 | |
| 4 | VKTX |
Viking Therapeutics, Inc.
|
2,288 | $89,254 | |
| 5 | INCY |
Incyte Corp
|
779 | $88,307 | |
| 6 | AUPH |
Aurinia Pharmaceuticals Inc.
|
2,675 | $45,394 | |
| 7 | AKTS |
Aktis Oncology, Inc.
This page
|
1,000 | $32,230 | |
| 8 | CRSP |
CRISPR Therapeutics AG
|
535 | $29,178 |
All Filings in AKTS
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $32,230 | 1,000 | Shares | Sole | 2026-07-14 | |
| 2026-03-31 | $17,890 | 1,000 | Shares | Sole | 2026-04-29 | |
| No filing history on record for this holder in this stock. | ||||||